Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

Launched by LUND UNIVERSITY HOSPITAL · May 21, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding two specific skin conditions: Mycosis Fungoides (MF) and Sézary Syndrome (SS). Researchers are trying to find out more about certain markers in the body that could help predict how these diseases will progress and how well they might respond to different treatments. The goal is to identify signs that can guide doctors in making better treatment decisions for patients with these conditions.

If you or a loved one is between 18 and 100 years old and has been diagnosed with MF or SS, you might be eligible to participate in this study. There's no need for specific lab results to join, and participants will be asked to provide written consent to ensure they understand what the study involves. Throughout the trial, participants can expect to contribute to important research that could improve care for others with these conditions. This trial is currently recruiting new participants, and everyone is welcome regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-100 years
• • Histologically confirmed (according to the World Health Organization (WHO)/EORTC classification) MF/SS stages I-IV
• • WHO performance status 0 -3
• • Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study.
• • Written informed consent according to International Conference on Harmonization (ICH)/(Good Clinical Practice (GCP), and Swedish regulations
• • No minimum or maximum required routine laboratory data
• Exclusion Criteria:
• • Not applicable. No exclusion criteria are specified.